Skip to main content
DAE HWA PHARM CO., LTD logo

DAE HWA PHARM CO., LTD — Investor Relations & Filings

Ticker · 067080 ISIN · KR7067080002 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-04-02 Notice of Dividend Amou…
Country KR South Korea
Listing KO 067080

About DAE HWA PHARM CO., LTD

http://www.dhpharm.co.kr

DAE HWA PHARM CO., LTD. is a pharmaceutical company focused on the research, development, and manufacturing of finished drug products. The company's core competency lies in its advanced Drug Delivery System (DDS) technologies, particularly its proprietary lipid-based self-emulsifying platform, DHLASED. This technology enabled the development of Liporaxel®, the world's first approved oral formulation of the anticancer agent paclitaxel. The company's portfolio also includes analgesics and anti-inflammatory drugs, such as the LOXONA trans-dermal patch, as well as aesthetic products like hyaluronic acid fillers and consumer health solutions.

Recent filings

Filing Released Lang Actions
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a regulatory filing from Daewha Pharmaceutical regarding a correction to a previously announced cash dividend. It specifies the dividend amount, the payment date (2025-04-25), and confirms the approval at the 41st Annual General Meeting. Since the primary purpose of the document is to announce the details and payment schedule of a dividend to shareholders, it falls under the 'Notice of Dividend Amount' category.
2025-04-02 Korean
[기재정정]타인에대한담보제공결정
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (Daehwa Pharmaceutical) regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It details a correction (정정신고) to a previous filing concerning the extension of collateral provided for a subsidiary's debt. This type of disclosure regarding financing, collateral, and capital structure changes falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but a direct regulatory disclosure of a corporate action.
2025-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM) for Daewha Pharmaceutical. It details the approval of financial statements, dividend resolutions, and board/auditor compensation. This falls under the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the outcome of shareholder votes at a general meeting.
2025-03-31 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (which is '적정' or 'unqualified'), financial highlights (assets, liabilities, equity, revenue, profit/loss), and details regarding the auditor. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2024
2025-03-21 Korean
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is titled '사업보고서' (Business Report) for the 41st fiscal year (2024-01-01 to 2024-12-31), submitted to the Financial Services Commission and Korea Exchange. It contains comprehensive sections including company overview, business details, financial statements, management discussion and analysis, and auditor's opinion. This structure corresponds to the standard Korean Annual Report (10-K equivalent). FY 2024
2025-03-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the sale of shares by a director (Kim Woon Jang) of Dae Hwa Pharmaceutical Co., Ltd. This type of filing, which reports personal share transactions by company insiders, is classified as 'Director's Dealing' (DIRS).
2025-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.